# Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma

> **NCT02892344** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 802 (actual)

## Conditions studied

- Mild Asthma

## Interventions

- **DRUG:** QMF149 150/80 μg
- **DRUG:** MF 200 μg

## Key facts

- **NCT ID:** NCT02892344
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-16
- **Primary completion:** 2018-11-05
- **Final completion:** 2018-11-30
- **Target enrollment:** 802 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02892344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02892344, "Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02892344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*